In this methodological article, the author reviews 1) the disproportionate impact that HIV/AIDS is having on communities of color in the United States, 2) what is known about the cost-effectiveness of HIV prevention interventions for racial/ethnic minority communities (including the methods used in these studies), and 3) the relative lack of methodological guidance in the field for conducting economic evaluation studies specifically for communities of color. The author finds that race/ethnicity affects cost-utility analyses in several heretofore unrecognized ways. In this article, methodological techniques to address these concerns are proposed. In particular, the author recommends cost-utility analytic strategies that maximize comparability among studies and avoid the introduction of methodological discrimination.
Get full access to this article
View all access options for this article.
References
1.
1. Centers for Disease Control and Prevention. HIV/AIDS Update: A Glance at the HIV Epidemic. Atlanta, GA: Centers for Disease Control and Prevention; 2001.
2.
2. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science. 1991;253:37-42.
3.
3. Centers for Disease Control and Prevention. HIV and AIDS—United States, 1981-2000. MMWR. 2001;50:430-434.
4.
4. US Census Bureau. Statistical Abstract of the United States: 2000. 120th ed. Washington (DC): US Census Bureau; 2001.
5.
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: US HIV and AIDS Cases Reported through December 2000. Vol. 12, no. 2. Atlanta (GA): Centers for Disease Control and Prevention; 2001.
6.
6. Anderson RN. Death: leading causes for 1999. National Vital Statistics Reports. 2001;49:11.
7.
7. Centers for Disease Control and Prevention. On the Front Lines: Fighting HIV/AIDS in African-American Communities. Atlanta, GA: Centers for Disease Control and Prevention; 1999.
8.
8. Office of Minority Health, Department of Health and Human Services. Health disparities. Available from: http://www.omhrc.gov/omhhome.htm
9.
9. Centers for Disease Control and Prevention. Compendium of HIV Prevention Interventions with Evidence of Effectiveness. Rev. ed. Atlanta (GA): Centers for Disease Control and Prevention; 1999.
10.
10. Mize SJS, Robinson BE, Bockting WO, Scheltema KE. Meta-analysis of the effectiveness of HIV prevention interventions for women. AIDS Care. 2002;14:163-180.
11.
11. Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998.
12.
12. Pinkerton SD, Holtgrave DR, Jemmott JB. Economic analysis of an HIV risk reduction intervention for male African American adolescents. J Acquir Immune Defic Syndr. 2000;25:164-172.
13.
13. Sweat M, O’Donnell C, O’Donnell L. Cost-effectiveness of a brief video-based HIV intervention for African American and Latino sexually transmitted disease clinic clients. AIDS. 2001;15:781-787.
14.
14. Holtgrave DR, Valdiserri RO, West GA. Quantitative economic evaluation of HIV prevention and treatment services: a review. Risk: Health, Safety & Environment. 1994;5:29-47.
15.
15. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. A review of the cost-effectiveness of interventions to prevent sexual transmission of HIV in the United States. AIDS Behav. In press.
16.
16. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2001;15:917-928.
17.
17. Kaplan EH. Economic evaluation and HIV prevention community planning: a policy analyst’s perspective. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 177-193.
18.
18. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996;86:1442-1445.
19.
19. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York: Oxford University Press; 1996.
20.
20. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1999.
21.
21. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
22.
22. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav. 1998;2:189-201.
23.
23. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
24.
24. Holtgrave DR, Qualls NL, Graham JD. Economic evaluation of HIV prevention programs. Ann Rev Public Health. 1996;17:467-488.
25.
25. Holtgrave DR. Setting priorities and community planning for HIV prevention programs. AIDS Public Policy J. 1994;9:145-151.
26.
26. Institute of Medicine, Committee on HIV Prevention Strategies in the United States. No Time to Lose: Getting More from HIV Prevention. Washington (DC): National Academy Press; 2001.
27.
27. Pinkerton SD, Holtgrave DR. Assessing the cost-effectiveness of HIV prevention interventions: A primer. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 33-43.
28.
28. Pinkerton SD, Abramson PR. Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Eval Rev. 1993;17:504-528.
29.
29. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications, and illustrations. In: Turner CF, Miller HG, Moses LE, eds. AIDS: Sexual Behavior and Intravenous Drug Use. Washington (DC): National Academy Press; 1989.
30.
30. Pinkerton SD, Abramson PR. The Bernoulli-process model of HIV transmission: applications and implications. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 13-32.
31.
31. Family Health International. AVERT: A Tool for Estimating Intervention Effects on the Reduction of HIV Transmission [manual and software]. Arlington (VA): Family Health International; 1998.
32.
32. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr. 1990;3:55-61.
33.
33. Whittington D, MacRae D Jr. The issue of standing in cost-benefit analysis. J Policy Anal Manage. 1986;5:665-682.
34.
34. Williams A. The “Fair Innings Argument deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson. Health Econ. 2001;10:583-585.
35.
35. Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference subgroups in cost-effectiveness analysis. Health Econ. 2001;10:317-324.
36.
36. Reinke WA. A multi-dimensional program evaluation model: considerations of cost-effectiveness, equity, quality and sustainability. Can J Program Eval. 1999;14:145-160.
37.
37. Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraints: is it equitable? N Engl J Med. 1996;334:1174-1177.
38.
38. Chadwick R, Levitt M. When drug treatment in the elderly is not cost-effective: an ethical dilemma in an environment of healthcare rationing. Drugs Aging. 1995;7:416-419.
39.
39. Pinkerton SD, Johnson-Masotti AP, Derse A, Layde PM. Ethical issues in cost-effectiveness analysis. Evaluation and Program Planning. In press.
40.
40. Gorsky RD. A method to measure the costs of counseling for HIV prevention. Pub Health Rep. 1996;111 Suppl 1:115-122.
41.
41. Kalichman SC, Rompa D, Cage M, et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med. 2001;21:84-92.
42.
42. Pinkerton SD, Holtgrave DR, DiFranceisco, Stevenson LY, Kelly JA. Cost-effectiveness of a community-level HIV risk reduction intervention. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York: Plenum; 1998. p 243-259.
43.
43. Holtgrave DR, Kelly JA. The cost-effectiveness of an HIV prevention intervention for gay men. AIDS Behav. 1997;1:173-180.
44.
44. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV prevention skills training for men who have sex with men. AIDS. 1997;11:347-357.
45.
45. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the U.S. J Acquir Immune Defic Syndr. 1998;18 Suppl 1;S133-S138.
46.
46. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62.
47.
47. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr. 2000;25:115-123.
48.
48. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28:124-131.
49.
49. Kleeberger CA, Phair JP, Strethdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIVantiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
50.
50. Laws MB, Wilson IB, Bowser DM, Kerr SE. Taking antiretroviral therapy for HIV infection: learning from patients’ stories. J Gen Intern Med. 2000;15:848-858.
51.
51. Centers for Disease Control and Prevention. Estimated life expectancy at birth in years, by race and sex: death-registration states, 1900-28, and United States, 1929-97. National Vital Statistics Report. 1999;47:32-33.
52.
52. Gold M, Franks P, Erickson P. Assessing the health of the nation: the predictive validity of a preference-based measure and self-rated health. Med Care. 1996;34:163-177.
53.
53. Cykert S, Joines JD, Kissling G, Hansen CJ. Racial differences in patients’ perceptions of debilitated health states. J Gen Inter Med. 1999;14:217-222.
54.
54. Andersen RM, Mullner RM, Cornelius LJ. Black-white differences in health status: methods or substance? Milbank Q. 1987;65 Suppl 1:72-99.
55.
55. Baron J. Does decision analysis have a race problem? J Gen Intern Med. 1999;14:260-261.
56.
56. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-265.
57.
57. Russell LB, Sisk JE. Modeling age differences in cost-effectiveness analysis. Int J Technol Assess Health Care. 2000;16:1158-1167.
58.
58. Sheldon TA, Smith PC. Equity in the allocation of health care resources. Health Econ. 2000;9:571-574.
